Vivo Capital LLC Grows Stock Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Key Points

• Vivo Capital LLC increased its holdings in Unicycive Therapeutics by 14.0%, owning approximately 9.43% of the company, equivalent to about $6.5 million.
• Unicycive Therapeutics stock has seen price volatility, with a 1-year low of $2.02 and a high of $11.00, currently trading around $4.06.
• Analysts have shown optimism, with HC Wainwright giving a "strong-buy" rating and a target price of $90.00 for the stock.

Vivo Capital LLC lifted its holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 14.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,370,152 shares of the company's stock after purchasing an additional 1,400,000 shares during the period. Unicycive Therapeutics comprises about 0.9% of Vivo Capital LLC's portfolio, making the stock its 27th largest holding. Vivo Capital LLC owned 9.43% of Unicycive Therapeutics worth $6,537,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of UNCY. Octagon Capital Advisors LP boosted its holdings in Unicycive Therapeutics by 16.8% in the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock worth $7,942,000 after buying an additional 1,441,000 shares during the last quarter. Acuta Capital Partners LLC boosted its holdings in Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after buying an additional 323,801 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock worth $8,253,000 after buying an additional 7,571,636 shares during the last quarter. Northern Trust Corp boosted its holdings in Unicycive Therapeutics by 142.4% in the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after buying an additional 34,183 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after buying an additional 100,679 shares during the last quarter. Hedge funds and other institutional investors own 40.42% of the company's stock.

Analyst Upgrades and Downgrades

UNCY has been the topic of several research analyst reports. Guggenheim initiated coverage on Unicycive Therapeutics in a report on Monday, April 21st. They issued a "buy" rating and a $60.00 price objective on the stock. HC Wainwright upgraded Unicycive Therapeutics to a "strong-buy" rating and set a $90.00 target price on the stock in a report on Tuesday, May 27th.

Unicycive Therapeutics Stock Up 0.7%

Shares of Unicycive Therapeutics stock traded up $0.03 on Friday, hitting $4.09. 225,053 shares of the company were exchanged, compared to its average volume of 432,081. The stock has a market capitalization of $51.70 million, a price-to-earnings ratio of -0.80 and a beta of 1.88. The company has a 50-day moving average price of $5.53 and a 200 day moving average price of $5.74. Unicycive Therapeutics, Inc. has a 1-year low of $2.02 and a 1-year high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.90. Research analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.